Last updated: 2026-09-07 18:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Celldex Therapeutics, Inc. (CLDX) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $39.67, with a market capitalization of $3.12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.10 to $45.14. This page covers its latest market performance, valuation, price trends and company information.
$3.12B | |
$38.96 | |
$582.60 | |
$1.50 | |
$39.37 | |
335.53K | |
996.70K | |
-- | |
$45.14 | |
$22.10 | |
-- | |
-- |
Celldex Therapeutics, Inc. (CLDX) last closed at $39.37 as of 2026-09-04 23:31:00, unchanged from the previous close of $39.37.
During the latest regular trading session, CLDX traded between $1.50 and $582.60, with a volume of 335.53K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Celldex Therapeutics, Inc. (CLDX) moved from $40.46 to $39.67, representing a decline of 1.95% ($0.79).
The stock traded between $38.74 and $41.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 489.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 76.3%
CLDX is currently trading at $39.67, placing it 76.3% of the way from its 52-week low of $22.10 to its 52-week high of $45.14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 198 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Celldex Therapeutics, Inc. (CLDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.